Transcription of HIGHLIGHTSOF PRESCRIBINGINFORMATION Hyperglycemia …
{{id}} {{{paragraph}}}
Example: bachelor of science
HIGHLIGHTSOF PRESCRIBINGINFORMATION Hyperglycemia …
HIGHLIGHTS OF PRESCRIBING INFORMATIONT hese highlights do not include all the information needed to use TOUJEO safely andeffectively. See full prescribing information for TOUJEO .TOUJEO (insulin glargine injection) U-300, for subcutaneous useInitial Approval: 2015 RECENT MAJOR CHANGES Dosage and Administration ( , )3/2018 Warnings and Precautions ( , )3/2018 INDICATIONS AND USAGE TOUJEO is a long-acting human insulin analog indicated to improve glycemic control in adults withdiabetes mellitus. (1)Limitations of Use:Not recommended for treating diabetic ketoacidosis. (1) DOSAGE AND ADMINISTRATION Individualize dose based on type of diabetes, metabolic needs, blood glucose monitoringresults and glycemic control goal. ( , , ) Administer subcutaneously once daily at any time during the day, at the same time every day.( ) Rotate injection sites to reduce the risk of lipodystrophy.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 12/2020 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Administration Instructions 2.2 General Dosing Instructions 2.3 Starting Dose in Insulin-Naive Pediatric and Adult Patients
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: